MedWatch

Lars Rasmussen sees no conflict in double chairmanship: "Although there's nothing to it, bad publicity could harm Ambu"

An anonymous email sent to several media, analysts and Ambu led the medtech company's chairman to resign from his post Thursday last week. In the email, an undisclosed group of equity holders question Rasmussen's impartiality. Personally, he refutes the notion that there's a conflict of interest.

Resigning Chairman of the Board at Ambu Lars Rasmussen. | Foto: Niels Hougaard/IND

After just one year in the role, Ambu's chairman of the board Lars Rasmussen has chosen not to run for another term at the medtech firm's general assembly in December. Rasmussen made this decision on Thursday afternoon last week, after receiving a particular email in his inbox.

A group of anonymous equity holders claimed that Rasmussen was subject to a conflict of interest by being the board chairman of both Coloplast and Ambu, after Coloplast, on the company's capital markets day, announced that it sees scopes as a potential future growth area for the firm.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier